Viatris (VTRS) Wins FDA Approval For RYZUMVI, Is The Upside Already Priced In?
Viatris (VTRS) stock is in focus after the U.S. FDA approved RYZUMVI, a phentolamine ophthalmic solution, for treating presbyopia in adults, extending its existing use in pharmacologically induced mydriasis.
The FDA decision came during an already strong run for Viatris, with the share price at US$18.66 and a 7 day share price return of 5.75% on top of a 1 month share price gain of 8.90%. Over a longer stretch, momentum has been positive, with the year to date share price return at 49.72% and the 1 year total shareholder return at 89.93%. This suggests that investors have been steadily marking the business higher as recent news and other developments have reset expectations around both opportunity and risk.
Scan beyond Viatris and this FDA catalyst by reviewing a curated group of healthcare companies in the list of solid balance sheet and fundamentals (25 results).
After such a sharp rerating and a fresh FDA catalyst in RYZUMVI, the question for Viatris holders is simple: Is most of the upside now in the rearview mirror, or does valuation still leave room ahead?
Most Popular Narrative: 4% Undervalued
Against Viatris' last close at $18.66, the most followed narrative pins fair value at $19.40, which points to a modest discount and puts the focus squarely on whether the pipeline and mix shift can justify that gap.
The company is well-positioned to benefit from sustained demand growth due to global population aging and increasing chronic disease prevalence, as demonstrated by positive late-stage pipeline developments in chronic disease, pain, and ophthalmology, setting the stage for long-term revenue growth through new branded and generic launches in large, underserved markets.
See why 47 investors see Viatris as 4% undervalued.
The narrative uses a 7.24% discount rate and arrives at a fair value of $19.40 per share, only slightly ahead of where Viatris currently trades. That small gap means most of the work is being done by assumptions around earnings turning positive and margins lifting from current loss-making levels rather than by assumptions of aggressive top line expansion.
Result: Fair Value of $19.40 (UNDERVALUED)
Still, the Viatris narrative can be knocked off course if pressure on mature generic pricing persists or if key late stage assets encounter regulatory or execution setbacks.
Find out about the key risks to this Viatris narrative.
Next Steps
Mixed messages in the Viatris story so far. Act promptly on the data, form your own stance, and weigh both sides through the 3 key rewards and 1 important warning sign.
Looking for more Viatris-size opportunities?
If you stop with Viatris, you only see one angle. Broaden your watchlist with fresh ideas that fit different portfolio goals and risk levels.
- Target steadier compounding potential by scanning resilient businesses in the 32 resilient stocks with low risk scores.
- Hunt for mispriced quality by reviewing companies trading below their estimated worth through the 33 high quality undervalued stocks.
- Strengthen your income stream by focusing on companies in the 8 dividend fortresses that pair sizeable yields with fundamental support.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com